earnings
Commercial Launches Fuel Growth: Vertex Diversifies Revenue Streams (VRTX Q1 2026 Earnings Call)
Vertex Pharmaceuticals Incorporated delivered strong financial results in Q1 2026, driven by expanding cystic fibrosis therapies and newly launched non-cystic fibrosis treatments. The company recorded Q1 total product revenue of $2.99 billion, representing robust global demand. In the U.S., total revenue grew by 7% year over year, further supported by recent label expansions for AlifTrack and TRIKAFTA that created a meaningful incremental opportunity of 800 newly eligible patients.